Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
June 07 2016 - 3:42PM
PR Newswire (US)
MISSISSAUGA, ON, June 7, 2016 /PRNewswire/ - Nuvo
Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial
healthcare company with a portfolio of commercial products and
pharmaceutical manufacturing capabilities, today announced that at
its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management
proxy circular dated May 4, 2016 were
elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
Daniel
Chicoine
|
3,977,783
|
46,583
|
98.84%
|
1.16%
|
David A.
Copeland
|
3,916,886
|
107,480
|
97.33%
|
2.67%
|
Anthony E.
Dobranowski
|
3,917,205
|
107,161
|
97.34%
|
2.66%
|
John C.
London
|
3,982,114
|
42,252
|
98.95%
|
1.05%
|
Dr. Jacques
Messier
|
3,985,773
|
38,593
|
99.04%
|
0.96%
|
Samira
Sakhia
|
3,987,856
|
36,510
|
99.09%
|
0.91%
|
About Nuvo Pharmaceuticals
Inc.
Nuvo (TSX:NRI) is a commercial healthcare company with
a portfolio of commercial products and pharmaceutical manufacturing
capabilities. Nuvo has three commercial products that are
available in a number of countries; Pennsaid 2%, Pennsaid and the
heated lidocaine/tetracaine patch. Pennsaid 2% is sold
in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available
for partnering in certain other territories around the world.
Nuvo manufactures Pennsaid for the global market and Pennsaid 2%
for the U.S. market at its FDA, Health Canada and EU approved
manufacturing facility in Varennes, Québec. For additional
information, please visit www.nuvopharmaceuticals.com.
SOURCE Nuvo Pharmaceuticals Inc.
Copyright 2016 PR Newswire